Skip to main content
NCBI home page
Heart logoLink to Heart
. 1997 Jun;77(6):517–522. doi: 10.1136/hrt.77.6.517

Safety of low dose heparin in elective coronary angioplasty.

K T Koch 1, J J Piek 1, R J de Winter 1, G K David 1, K Mulder 1, J G Tijssen 1, K I Lie 1
PMCID: PMC484793  PMID: 9227294

Abstract

OBJECTIVES: To evaluate the safety of a low dose of heparin in consecutive stable patients undergoing elective percutaneous transluminal coronary angioplasty (PTCA). DESIGN: Open prospective study in a single centre. PATIENTS: 1375 consecutive patients had elective PTCA (1952 lesions: type A 11%, B1 34%, B2 36%, and C 19%). There were no angiographic exclusion criteria. INTERVENTIONS: A bolus of 5000 IU heparin was used as the standard anticoagulation regimen during PTCA. The sheaths were removed immediately after successful completion of the procedure. Prolongation of heparin treatment was left to the operator's discretion. MAIN OUTCOME MEASURES: Procedural success was defined as < 50% residual stenosis without death from any cause, acute myocardial infarction, urgent coronary bypass surgery, or repeat angioplasty within 48 hours for acute recurrent ischaemia; the need for prolonged heparinisation; and the occurrence of puncture site complications. RESULTS: Procedural success without clinical events was achieved in 90% of patients. Mortality was 0.3%; coronary bypass surgery was performed in 1.7% of the procedures. The rate of myocardial infarction was 3.3%; repeat angioplasty within 48 hours was carried out in 0.7% of patients. A total of 89.1% of the patients were treated according to the protocol. Prolonged treatment with heparin was considered necessary in 123 patients (8.9%). Repeat angioplasty for abrupt closure was performed in two patients shortly after sheath removal and in two during prolonged heparinisation. Puncture site complications occurred in 2.1% of patients (low dose heparin 1.9% and prolonged heparinisation 4.9%). CONCLUSION: Elective PTCA can be safely performed using a low dose of heparin, with a negligible risk for subacute closure. Low dose heparin may reduce the incidence of puncture site complications, shorten hospitalisation, and enable out-patient angioplasty.

Full text

PDF
517

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abdelmeguid A. E., Ellis S. G., Sapp S. K., Whitlow P. L., Topol E. J. Defining the appropriate threshold of creatine kinase elevation after percutaneous coronary interventions. Am Heart J. 1996 Jun;131(6):1097–1105. doi: 10.1016/s0002-8703(96)90083-6. [DOI] [PubMed] [Google Scholar]
  2. Braunwald E. Unstable angina. A classification. Circulation. 1989 Aug;80(2):410–414. doi: 10.1161/01.cir.80.2.410. [DOI] [PubMed] [Google Scholar]
  3. Bull B. S., Huse W. M., Brauer F. S., Korpman R. A. Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg. 1975 May;69(5):685–689. [PubMed] [Google Scholar]
  4. Bull B. S., Korpman R. A., Huse W. M., Briggs B. D. Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg. 1975 May;69(5):674–684. [PubMed] [Google Scholar]
  5. Detre K., Holubkov R., Kelsey S., Cowley M., Kent K., Williams D., Myler R., Faxon D., Holmes D., Jr, Bourassa M. Percutaneous transluminal coronary angioplasty in 1985-1986 and 1977-1981. The National Heart, Lung, and Blood Institute Registry. N Engl J Med. 1988 Feb 4;318(5):265–270. doi: 10.1056/NEJM198802043180501. [DOI] [PubMed] [Google Scholar]
  6. Dougherty K. G., Gaos C. M., Bush H. S., Leachman D. R., Ferguson J. J. Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparin. Cathet Cardiovasc Diagn. 1992 Aug;26(4):260–263. doi: 10.1002/ccd.1810260404. [DOI] [PubMed] [Google Scholar]
  7. Ellis S. G., Roubin G. S., Wilentz J., Douglas J. S., Jr, King S. B., 3rd Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. Am Heart J. 1989 Apr;117(4):777–782. doi: 10.1016/0002-8703(89)90612-1. [DOI] [PubMed] [Google Scholar]
  8. Ferguson J. J., Dougherty K. G., Gaos C. M., Bush H. S., Marsh K. C., Leachman D. R. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 1994 Apr;23(5):1061–1065. doi: 10.1016/0735-1097(94)90590-8. [DOI] [PubMed] [Google Scholar]
  9. Fischman D. L., Leon M. B., Baim D. S., Schatz R. A., Savage M. P., Penn I., Detre K., Veltri L., Ricci D., Nobuyoshi M. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med. 1994 Aug 25;331(8):496–501. doi: 10.1056/NEJM199408253310802. [DOI] [PubMed] [Google Scholar]
  10. Friedman H. Z., Cragg D. R., Glazier S. M., Gangadharan V., Marsalese D. L., Schreiber T. L., O'Neill W. W. Randomized prospective evaluation of prolonged versus abbreviated intravenous heparin therapy after coronary angioplasty. J Am Coll Cardiol. 1994 Nov 1;24(5):1214–1219. doi: 10.1016/0735-1097(94)90101-5. [DOI] [PubMed] [Google Scholar]
  11. Frierson J. H., Dimas A. P., Simpfendorfer C. C., Pearce G., Miller M., Franco I. Is aggressive heparinization necessary for elective PTCA? Cathet Cardiovasc Diagn. 1993 Apr;28(4):279–282. doi: 10.1002/ccd.1810280403. [DOI] [PubMed] [Google Scholar]
  12. Gabliani G., Deligonul U., Kern M. J., Vandormael M. Acute coronary occlusion occurring after successful percutaneous transluminal coronary angioplasty: temporal relationship to discontinuation of anticoagulation. Am Heart J. 1988 Sep;116(3):696–700. doi: 10.1016/0002-8703(88)90326-2. [DOI] [PubMed] [Google Scholar]
  13. Klein L. W., Kramer B. L., Howard E., Lesch M. Incidence and clinical significance of transient creatine kinase elevations and the diagnosis of non-Q wave myocardial infarction associated with coronary angioplasty. J Am Coll Cardiol. 1991 Mar 1;17(3):621–626. doi: 10.1016/s0735-1097(10)80174-3. [DOI] [PubMed] [Google Scholar]
  14. Kresowik T. F., Khoury M. D., Miller B. V., Winniford M. D., Shamma A. R., Sharp W. J., Blecha M. B., Corson J. D. A prospective study of the incidence and natural history of femoral vascular complications after percutaneous transluminal coronary angioplasty. J Vasc Surg. 1991 Feb;13(2):328–335. [PubMed] [Google Scholar]
  15. Kussmaul W. G., 3rd, Buchbinder M., Whitlow P. L., Aker U. T., Heuser R. R., King S. B., Kent K. M., Leon M. B., Kolansky D. M., Sandza J. G., Jr Rapid arterial hemostasis and decreased access site complications after cardiac catheterization and angioplasty: results of a randomized trial of a novel hemostatic device. J Am Coll Cardiol. 1995 Jun;25(7):1685–1692. doi: 10.1016/0735-1097(95)00101-9. [DOI] [PubMed] [Google Scholar]
  16. Lette J., Waters D., Cerino M., Picard M., Champagne P., Lapointe J. Preoperative coronary artery disease risk stratification based on dipyridamole imaging and a simple three-step, three-segment model for patients undergoing noncardiac vascular surgery or major general surgery. Am J Cardiol. 1992 Jun 15;69(19):1553–1558. doi: 10.1016/0002-9149(92)90702-z. [DOI] [PubMed] [Google Scholar]
  17. McGarry T. F., Jr, Gottlieb R. S., Morganroth J., Zelenkofske S. L., Kasparian H., Duca P. R., Lester R. M., Kreulen T. H. The relationship of anticoagulation level and complications after successful percutaneous transluminal coronary angioplasty. Am Heart J. 1992 Jun;123(6):1445–1451. doi: 10.1016/0002-8703(92)90793-u. [DOI] [PubMed] [Google Scholar]
  18. Muller D. W., Shamir K. J., Ellis S. G., Topol E. J. Peripheral vascular complications after conventional and complex percutaneous coronary interventional procedures. Am J Cardiol. 1992 Jan 1;69(1):63–68. doi: 10.1016/0002-9149(92)90677-q. [DOI] [PubMed] [Google Scholar]
  19. Myler R. K., Shaw R. E., Stertzer S. H., Hecht H. S., Ryan C., Rosenblum J., Cumberland D. C., Murphy M. C., Hansell H. N., Hidalgo B. Lesion morphology and coronary angioplasty: current experience and analysis. J Am Coll Cardiol. 1992 Jun;19(7):1641–1652. doi: 10.1016/0735-1097(92)90631-v. [DOI] [PubMed] [Google Scholar]
  20. Narins C. R., Hillegass W. B., Jr, Nelson C. L., Tcheng J. E., Harrington R. A., Phillips H. R., Stack R. S., Califf R. M. Relation between activated clotting time during angioplasty and abrupt closure. Circulation. 1996 Feb 15;93(4):667–671. doi: 10.1161/01.cir.93.4.667. [DOI] [PubMed] [Google Scholar]
  21. Ogilby J. D., Kopelman H. A., Klein L. W., Agarwal J. B. Adequate heparinization during PTCA: assessment using activated clotting times. Cathet Cardiovasc Diagn. 1989 Dec;18(4):206–209. doi: 10.1002/ccd.1810180403. [DOI] [PubMed] [Google Scholar]
  22. Omoigui N. A., Califf R. M., Pieper K., Keeler G., O'Hanesian M. A., Berdan L. G., Mark D. B., Talley J. D., Topol E. J. Peripheral vascular complications in the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I). J Am Coll Cardiol. 1995 Oct;26(4):922–930. doi: 10.1016/0735-1097(95)00263-4. [DOI] [PubMed] [Google Scholar]
  23. Rath B., Bennett D. H. Monitoring the effect of heparin by measurement of activated clotting time during and after percutaneous transluminal coronary angioplasty. Br Heart J. 1990 Jan;63(1):18–21. doi: 10.1136/hrt.63.1.18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Serruys P. W., Klein W., Tijssen J. P., Rutsch W., Heyndrickx G. R., Emanuelsson H., Ball S. G., Decoster O., Schroeder E., Liberman H. Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. A multicenter randomized double-blind placebo-controlled trial. Circulation. 1993 Oct;88(4 Pt 1):1588–1601. doi: 10.1161/01.cir.88.4.1588. [DOI] [PubMed] [Google Scholar]
  25. Serruys P. W., de Jaegere P., Kiemeneij F., Macaya C., Rutsch W., Heyndrickx G., Emanuelsson H., Marco J., Legrand V., Materne P. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med. 1994 Aug 25;331(8):489–495. doi: 10.1056/NEJM199408253310801. [DOI] [PubMed] [Google Scholar]
  26. Topol E. J., Leya F., Pinkerton C. A., Whitlow P. L., Hofling B., Simonton C. A., Masden R. R., Serruys P. W., Leon M. B., Williams D. O. A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease. The CAVEAT Study Group. N Engl J Med. 1993 Jul 22;329(4):221–227. doi: 10.1056/NEJM199307223290401. [DOI] [PubMed] [Google Scholar]
  27. Vainer J., Fleisch M., Gunnes P., Ramamurthy S., Garachemani A., Kaufmann U. P., Meyer B. J., Lüscher T. F., Meier B. Low-dose heparin for routine coronary angioplasty and stenting. Am J Cardiol. 1996 Oct 15;78(8):964–966. doi: 10.1016/s0002-9149(96)00480-8. [DOI] [PubMed] [Google Scholar]
  28. Wilson J. M., Dougherty K. G., Ellis K. O., Ferguson J. J. Activated clotting times in acute coronary syndromes and percutaneous transluminal coronary angioplasty. Cathet Cardiovasc Diagn. 1995 Jan;34(1):1–5. doi: 10.1002/ccd.1810340302. [DOI] [PubMed] [Google Scholar]
  29. Wyman R. M., Safian R. D., Portway V., Skillman J. J., McKay R. G., Baim D. S. Current complications of diagnostic and therapeutic cardiac catheterization. J Am Coll Cardiol. 1988 Dec;12(6):1400–1406. doi: 10.1016/s0735-1097(88)80002-0. [DOI] [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES